Dr. Joyce N. Barlin, M.D.
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Albany Medical College of Union University (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 218
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: Albany Medical College of Union University
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
NY license 256046
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Peter's Hospital Albany, NY
- Samaritan Hospital of Troy, New York Troy, NY
- Saratoga Hospital Saratoga Springs, NY
- Ellis Hospital Schenectady, NY
- Columbia Memorial Hospital Hudson, NY
Medical groups
- St. Peter's Health PArtners Medical Associates, P.c. (487 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 218
- Services billed
- 18,500
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, paclitaxel, 1 mg | 6,474 | 15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 880 | 22 |
| Injection, granisetron hydrochloride, 100 mcg | 461 | 22 |
| Injection, carboplatin, 50 mg | 252 | 13 |
| Established patient office or other outpatient visit, 20-29 minutes | 195 | 131 |
| Administration of chemotherapy into vein, 1 hour or less | 91 | 36 |
| Established patient office or other outpatient visit, 30-39 minutes | 79 | 61 |
| Infusion, normal saline solution, 250 cc | 65 | 25 |
| Telephone medical discussion with physician, 5-10 minutes | 60 | 45 |
| Injection of additional new drug or substance into vein | 52 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Albany, NY | 69 |
| Tramadol Hcl Other prescribers in Albany, NY | 49 |
| Triamcinolone Acetonide Other prescribers in Albany, NY | 25 |
| Megestrol Acetate Other prescribers in Albany, NY | 22 |
| Eliquis (apixaban) Other prescribers in Albany, NY | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 28 payments worth $44,214 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $31,127 |
|---|---|
| Merck Sharp & Dohme LLC | $6,055 |
| Daiichi Sankyo Inc. | $3,500 |
| Corcept Therapeutics | $3,317 |
| AbbVie Inc. | $215 |
| Compensation for services other than consulting (speaking, faculty) | $33,640 |
|---|---|
| Consulting Fee | $6,817 |
| Travel and Lodging | $2,902 |
| Food and Beverage | $830 |
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty) LYNPARZA · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| AstraZeneca Pharmaceuticals LP Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) LYNPARZA · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| AstraZeneca Pharmaceuticals LP May 1, 2025 | Compensation for services other than consulting (speaking, faculty) LYNPARZA · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| AstraZeneca Pharmaceuticals LP Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) LYNPARZA · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| Merck Sharp & Dohme LLC Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $5,760 |
| Corcept Therapeutics Apr 8, 2025 | Consulting Fee | $2,117 |
| Daiichi Sankyo Inc. Feb 20, 2025 | Consulting Fee | $2,100 |
| AstraZeneca Pharmaceuticals LP Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) LYNPARZA · Oncology Company’s descriptionSpeaker Fee | $1,640 |
| Daiichi Sankyo Inc. Feb 13, 2025 | Consulting Fee | $1,400 |
| AstraZeneca Pharmaceuticals LP Apr 24, 2025 | Travel and Lodging LYNPARZA · Oncology · travel to Garden City, NY · in-kind Company’s descriptionSpeaker Expenses | $1,172 |
All 19 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Corcept Therapeutics Dec 16, 2025 | Consulting Fee | $600 |
| AstraZeneca Pharmaceuticals LP Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) LYNPARZA · Oncology Company’s descriptionSpeaker Fee | $1,640 |
| AstraZeneca Pharmaceuticals LP Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) LYNPARZA · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| AstraZeneca Pharmaceuticals LP Nov 13, 2025 | Travel and Lodging LYNPARZA · Oncology · travel to New York, NY · in-kind Company’s descriptionSpeaker Expenses | $1,164 |
| Merck Sharp & Dohme LLC Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $5,760 |
| Merck Sharp & Dohme LLC Jul 16, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Foxborough, MA | $150 |
| AstraZeneca Pharmaceuticals LP Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty) LYNPARZA · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| AstraZeneca Pharmaceuticals LP Jun 24, 2025 | Travel and Lodging LYNPARZA · Oncology · travel to Nyack, NY | $190 |
| AstraZeneca Pharmaceuticals LP Jun 24, 2025 | Travel and Lodging LYNPARZA · Oncology · travel to Nyack, NY | $11.02 |
| AstraZeneca Pharmaceuticals LP May 1, 2025 | Compensation for services other than consulting (speaking, faculty) LYNPARZA · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| AstraZeneca Pharmaceuticals LP Apr 29, 2025 | Travel and Lodging LYNPARZA · Oncology · travel to Syracuse, NY | $202 |
| AstraZeneca Pharmaceuticals LP Apr 29, 2025 | Travel and Lodging LYNPARZA · Oncology · travel to Syracuse, NY | $12.66 |
| AstraZeneca Pharmaceuticals LP Apr 24, 2025 | Travel and Lodging LYNPARZA · Oncology · travel to Garden City, NY · in-kind Company’s descriptionSpeaker Expenses | $1,172 |
| AstraZeneca Pharmaceuticals LP Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) LYNPARZA · Oncology Company’s descriptionSpeaker Fee | $6,560 |
| Corcept Therapeutics Apr 8, 2025 | Consulting Fee | $2,117 |
| Merck Sharp & Dohme LLC Apr 8, 2025 | Education KEYTRUDA · ONCOLOGY · in-kind | $25.70 |
| Corcept Therapeutics Mar 26, 2025 | Consulting Fee | $600 |
| Daiichi Sankyo Inc. Feb 20, 2025 | Consulting Fee | $2,100 |
| Daiichi Sankyo Inc. Feb 13, 2025 | Consulting Fee | $1,400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $81,921 in research payments for these studies, mostly to the institutions running them.
- A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Daiichi Sankyo Inc. · Active, not recruiting · NCT06660654 - A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
AbbVie Inc. · Active, not recruiting · NCT06365853 - A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Karyopharm Therapeutics Inc. - A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Pharmaand GmbH · Active, not recruiting · NCT03522246 - Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie Inc. · Active, not recruiting · NCT05445778 - A phase 3, randomized, double-blind, multicenter study of dostarlimab
GlaxoSmithKline, LLC. - 1NSPIRE study: investigating 1L maintenance niraparib safety and patie
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.